Reni J. Benjamin
Stock Analyst at Citizens
(4.14)
# 3,478
Out of 5,182 analysts
26
Total ratings
54.17%
Success rate
17.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Reni J. Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STRO Sutro Biopharma | Maintains: Market Outperform | $35 → $41 | $33.33 | +23.01% | 2 | Apr 23, 2026 | |
| WHWK Whitehawk Therapeutics | Initiates: Market Outperform | $8 | $4.03 | +98.51% | 1 | Apr 16, 2026 | |
| ALLO Allogene Therapeutics | Maintains: Market Outperform | $5 → $8 | $2.31 | +246.32% | 1 | Apr 14, 2026 | |
| BCAX Bicara Therapeutics | Reiterates: Market Outperform | $31 | $22.65 | +36.87% | 2 | Mar 31, 2026 | |
| IMMX Immix Biopharma | Reiterates: Market Outperform | $23 | $9.85 | +133.50% | 1 | Mar 27, 2026 | |
| LYEL Lyell Immunopharma | Initiates: Market Outperform | $34 | $22.41 | +51.72% | 1 | Mar 9, 2026 | |
| IOVA Iovance Biotherapeutics | Upgrades: Market Outperform | $5 | $3.44 | +45.35% | 2 | Mar 3, 2026 | |
| IMMP Immutep | Initiates: Market Outperform | $10 | $0.57 | +1,645.20% | 2 | Feb 23, 2026 | |
| SMMT Summit Therapeutics | Reiterates: Market Outperform | $40 | $22.08 | +81.16% | 4 | Jan 30, 2026 | |
| ZYME Zymeworks | Initiates: Market Outperform | $32 | $28.10 | +13.88% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $348 → $396 | $300.80 | +31.65% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $5 → $8 | $3.29 | +143.16% | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $24 | $9.26 | +159.18% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $129.06 | - | 1 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $3 | $0.81 | +269.00% | 1 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $3 | $4.70 | -36.17% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.87 | - | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $22 → $10 | $4.84 | +106.61% | 1 | Aug 12, 2025 |
Sutro Biopharma
Apr 23, 2026
Maintains: Market Outperform
Price Target: $35 → $41
Current: $33.33
Upside: +23.01%
Whitehawk Therapeutics
Apr 16, 2026
Initiates: Market Outperform
Price Target: $8
Current: $4.03
Upside: +98.51%
Allogene Therapeutics
Apr 14, 2026
Maintains: Market Outperform
Price Target: $5 → $8
Current: $2.31
Upside: +246.32%
Bicara Therapeutics
Mar 31, 2026
Reiterates: Market Outperform
Price Target: $31
Current: $22.65
Upside: +36.87%
Immix Biopharma
Mar 27, 2026
Reiterates: Market Outperform
Price Target: $23
Current: $9.85
Upside: +133.50%
Lyell Immunopharma
Mar 9, 2026
Initiates: Market Outperform
Price Target: $34
Current: $22.41
Upside: +51.72%
Iovance Biotherapeutics
Mar 3, 2026
Upgrades: Market Outperform
Price Target: $5
Current: $3.44
Upside: +45.35%
Immutep
Feb 23, 2026
Initiates: Market Outperform
Price Target: $10
Current: $0.57
Upside: +1,645.20%
Summit Therapeutics
Jan 30, 2026
Reiterates: Market Outperform
Price Target: $40
Current: $22.08
Upside: +81.16%
Zymeworks
Dec 3, 2025
Initiates: Market Outperform
Price Target: $32
Current: $28.10
Upside: +13.88%
Nov 7, 2025
Maintains: Market Outperform
Price Target: $348 → $396
Current: $300.80
Upside: +31.65%
Oct 30, 2025
Maintains: Market Outperform
Price Target: $5 → $8
Current: $3.29
Upside: +143.16%
Oct 20, 2025
Reiterates: Market Outperform
Price Target: $24
Current: $9.26
Upside: +159.18%
Aug 22, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $129.06
Upside: -
Aug 21, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $0.81
Upside: +269.00%
Aug 18, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $4.70
Upside: -36.17%
Aug 13, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $4.87
Upside: -
Aug 12, 2025
Maintains: Market Outperform
Price Target: $22 → $10
Current: $4.84
Upside: +106.61%